
Opinion|Videos|January 22, 2025
Overview of the DESTINY-Breast12 Study
Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand treatment options for this subgroup.





































